Perianal Fistulizing Crohn's Disease: Anti-TNF Precedent Against a Newer Mechanism
A single patient with newly diagnosed perianal fistulizing Crohn's disease, testing whether anti-TNF therapy's decades of fistula-specific evidence still outweighs a newer IL-23-selective biologic's cleaner safety profile.
Camille R., a 27-year-old woman in veterinary school, was diagnosed with Crohn's disease six months ago after a workup for perianal pain and drainage that started during her clinical rotations and that she'd initially assumed was a simple abscess. Exam and pelvic MRI confirmed two complex perianal fistulous tracts, and a colorectal surgeon has already placed draining setons to control acute sepsis risk while medical therapy is arranged. She has no other significant medical history, has never been on a biologic, and is candid that the timing couldn't be worse — she's mid-way through a demanding clinical year and wants a treatment plan that actually controls the fistulas, not one that manages them indefinitely.
Biologic selection for perianal fistulizing Crohn's disease isn't a simple extension of choosing a biologic for luminal disease, because fistula closure is a distinct, generally harder-to-achieve outcome than mucosal healing, with its own specific trial evidence rather than an inference from luminal remission rates. Infliximab has by far the deepest evidence base here: Present et al. (NEJM 1999) established fistula closure as an infliximab endpoint in its own right, and ACCENT II (Sands et al., NEJM 2004) then showed maintenance infliximab sustained that closure — two trials built around the outcome Camille actually needs, not around luminal remission with fistula data reported afterward. Add decades of accumulated experience using it alongside surgical seton management, which is precisely the situation she is in.
Risankizumab, an IL-23 p19-subunit inhibitor approved more recently for Crohn's disease, carries a materially cleaner long-term infection and malignancy safety profile than anti-TNF therapy — a real consideration for a 27-year-old who may be on a biologic for decades — but its own fistula-specific evidence is post hoc analysis of the ADVANCE and MOTIVATE induction trials rather than a trial designed around fistula closure, which is a genuinely different tier of evidence from the one infliximab occupies here. The question for Camille isn't whether newer mechanisms will eventually close that evidence gap; it's whether, starting from zero biologic exposure today, the gap is already close enough to choose around.
Joint GI/colorectal clinic, choosing first biologic for fistulizing disease
I'd start infliximab. It has by far the deepest fistula-specific trial evidence of any biologic — Present in 1999 and then ACCENT II for maintenance, both built around fistula closure rather than inferring it from luminal remission — and decades of coordinated use alongside seton management, which is exactly the situation Camille is in now with her setons already placed.
I'd want risankizumab genuinely considered here, not dismissed outright. She's 27 and may be on a biologic for decades — IL-23-selective agents carry a materially cleaner long-term infection and malignancy safety profile than anti-TNF therapy, and that compounds meaningfully over that kind of timeline. Its fistula data is real, even if it's a post hoc read of ADVANCE and MOTIVATE rather than a fistula trial.
I take the long-term safety argument seriously, and I don't think it's wrong — it's just not yet decisive against a fistula-specific evidence gap this wide, for a patient starting biologic therapy from zero with active, complex fistulizing disease right now. Risankizumab's fistula data comes out of post hoc analysis of ADVANCE and MOTIVATE, which is considerably less mature than two trials built around fistula closure as the endpoint they were powered on. I'd start infliximab now, and I want it on record that this isn't a permanent verdict against risankizumab — as its own fistula-specific evidence matures, that calculus could genuinely shift for the next patient, or even for Camille herself down the line.
Agreed: infliximab induction started with a short adjunctive ciprofloxacin course, setons left in place per the surgeon's plan until MRI confirms adequate fistula response, typically reassessed around six months. The pharmacologist's long-term safety argument for risankizumab was documented explicitly in the chart as a live consideration for future biologic decisions, not a settled question closed today — worth revisiting if Camille's disease requires a change in mechanism down the line.